We are determined to change the way cancer patients are diagnosed
Barcode Diagnostics is led by a talented management team and backed by highly experienced advisors with proven success in medical innovation. The company has already run successful pre-clinical trials indicating that the technology is effective in generating personalized and effective treatment protocols. Barcode Diagnostics owns a robust patent portfolio including one PCT, and two patents pending, and has filed an FDA pre-submission. The company aims for a first-in-human by 2020.
The technology was conceived in the Technion (the Israel institute of Technology) and the company is located in the NGT3VC in Nazareth Israel.